Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update

Otonomy (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial results for the quarter ended March 31, 2018 and provided an update on its corporate activities and product pipeline.

As quoted in the press release:

“We completed a productive first quarter by obtaining clarity from FDA on the registration requirements for OTIVIDEX in Ménière’s disease, receiving approval for OTIPRIO in acute otitis externa, and advancing our multiple development programs for hearing loss and tinnitus,” said David A. Weber, Ph.D., president and CEO of Otonomy. “We are on track with our efforts to initiate the remaining pivotal trial for OTIVIDEX and are making good progress towards the completion of a partnering transaction for OTIPRIO.”

Click here to read the full press release.